PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST

@article{Cunningham1987PREVENTIONOE,
  title={PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST},
  author={Deborah H. Cunningham and Andrew K Pople and Hubert T. Ford and Jeremy Hawthorn and R C Coombes},
  journal={The Lancet},
  year={1987},
  volume={329},
  pages={1461-1463}
}
15 patients receiving cytotoxic drugs (other than cisplatin) that had previously produced nausea and vomiting refractory to first-line antiemetics were given a selective 5-HT3 receptor antagonist (GR38032F), 4 mg intravenously and 4 mg orally, immediately before chemotherapy, the oral dose being repeated 5 and 10 h later. Nausea, vomiting, and side-effects were recorded for the ensuing 24 h. The 15 patients received a total of thirty-one courses of chemotherapy. Only 1 patient vomited. The only… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 36 CITATIONS

5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.

  • Expert opinion on drug safety
  • 2014
VIEW 19 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Drugs Affecting 5-HT Systems

VIEW 1 EXCERPT
CITES BACKGROUND

Psychosis in Parkinson's disease.

  • Journal of geriatric psychiatry and neurology
  • 2004
VIEW 1 EXCERPT
CITES BACKGROUND